Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.38 |
| ▸ | CTSC | P53634 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021917 | 0.75 | CTSC (0.37) | HSD11B1CTSCCYP3A4CYP2C19ADRA2A | |
| SCHEMBL6781555 | 0.69 | HSD11B1 (0.33) | HSD11B1CTSCCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5507377 | 0.66 | HSD11B1 (0.39) | HSD11B1CTSCCYP3A4CYP2C19ADRA2A | |
| SCHEMBL4028733 | 0.66 | CTSC (0.31) | CTSC | |
| SCHEMBL27593899 | 0.65 | HSD11B1 (0.40) | HSD11B1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30960368 | 0.65 | GRIN2B (0.44) | HSD11B1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17033075 | 0.65 | HSD11B1 (0.43) | HSD11B1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17031763 | 0.64 | TAAR1 (0.38) | HSD11B1CTSCCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4025459 | 0.63 | SLC6A3 (0.35) | KMT2A | |
| SCHEMBL6664040 | 0.63 | CTSC (0.36) | HSD11B1CTSCCYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070219262-A1 | omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists | ALLERGAN, INC. | 2007-09-20 | — | — | US | disclosed |
| US-7223746-B2 | Omega cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1438104-B1 | CO-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7022726-B2 | ω-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1442033-B1 | OMEGA-CYCLOALKYL 17-HETEROARYL PROSTAGLANDIN E2 ANALOGS AS EP2-RECEPTOR AGONISTS | ALLERGAN INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2005-05-26 | — | — | US | disclosed |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN INC. | 2004-06-03 | — | — | US | disclosed |
| US-6710072-B2 | VISION DEFECTS | ALLERGAN, INC. | 2004-03-23 | — | — | US | disclosed |
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6586462-B2 | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | ALLERGAN, INC. | 2002-12-12 | — | — | US | disclosed |
| US-6376533-B1 | VISION DEFECTS | ALLERGAN SALES, INC. | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130239-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | HSD11B1 390/4885CTSC 3918/4885CYP3A4 264/4885 |
| US-20020187961-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER1, PTGER3 | HSD11B1 337/4885CTSC 3367/4885CYP3A4 1287/4885 |
| US-20070219262-A1 | omega-Cycloalkyl 17-Heteroaryl Prostaglandin E2 Analogs as EP2-Receptor Agonists | PTGER4, PTGER2, LTB4R2 | HSD11B1 355/4885CTSC 4423/4885CYP3A4 96/4885 |
| US-20050113338-A1 | Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER4, PTGER2, LTB4R2 | HSD11B1 321/4885CTSC 4524/4885CYP3A4 98/4885 |
| US-20040106580-A1 | Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists | PTGER2, PTGER4, PTGER1 | HSD11B1 391/4885CTSC 3888/4885CYP3A4 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.